The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)

Conditions

  • Neurotrophic Keratopathy

Intervention

  • RGN-259
  • Placebo

Principal Investigator

  • Affeldt, John

Sponsor

  • ReGenTree, LLC

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.